글로벌 에피제네틱스 시장 – 2031년까지의 산업 동향 및 예측

에피제네틱스 시장 분석 및 규모

후생유전학 시장은 기술 발전으로 인해 기하급수적으로 성장하고 있습니다. CRISPR 기반 후생유전체 편집과 같은 최신 방법은 연구와 응용 분야에 혁명을 일으키고 있습니다. 이러한 획기적인 발전은 유전자 발현의 정확한 조작을 가능하게 하여 질병, 노화 및 개인화된 의학에 대한 전례 없는 통찰력을 제공합니다. 혁신적인 솔루션에 대한 수요가 급증함에 따라 후생유전학 시장은 상당한 확장과 변혁적 영향을 받을 준비가 되었습니다.                               

글로벌 에피제네틱스 시장 규모는 2023년에 158억 3천만 달러로 평가되었으며, 2031년까지 689억 8천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 20.20%입니다. 이는 시장 가치를 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

시장 정의

후생유전학은 유전 코드 자체의 변형을 수반하지 않는 유전자 활동의 변화를 연구하는 학문입니다. 이러한 변화는 환경, 생활 방식, 경험과 같은 다양한 요인의 영향을 받을 수 있습니다. 이는 유전자 발현에 영향을 미칠 수 있으며, 결과적으로 특성과 건강 결과에 영향을 미칠 수 있습니다. 후생유전학을 이해하는 것은 유기체의 발달과 질병에 대한 감수성을 형성하는 데 있어 본성과 양육 간의 복잡한 상호 작용을 밝히는 데 필수적입니다.           

에피제네틱스 시장 동향

운전자

• 약물 발견 및 개발 증가

약물 발견을 위한 실행 가능한 표적으로서 후생유전적 변형의 인식은 시장 성장을 촉진하고 있습니다. 제약 회사는 획기적인 치료법을 개발하기 위해 후생유전적 연구에 많은 투자를 하고 있습니다. 예를 들어, 암 치료에서 DNA 메틸화를 표적으로 하는 아자시티딘 과 데시타빈과 같은 약물은 치료 옵션에 혁명을 일으켜 시장의 잠재력을 입증했습니다. 마찬가지로 신경계 질환과 자가면역 질환에 대한 후생유전적 치료법에 대한 연구가 가속화되어 시장 확장을 더욱 촉진하고 있습니다.

• 다른 오믹스 기술과의 통합

유전체학 및 프로테오믹스 와 같은 다른 오믹스 기술과 에피제네틱스를 통합하면 생물학적 시스템에 대한 이해가 향상됩니다. 이러한 시너지는 다중 오믹스 플랫폼에 대한 수요를 촉진하여 시장 성장을 촉진합니다. 예를 들어, 에피제네틱 데이터를 유전체 및 전사체 데이터와 결합하면 연구자는 복잡한 유전자 조절 네트워크를 밝혀 질병 이해 및 약물 개발에 획기적인 진전을 이룰 수 있으며, 시장을 더욱 발전시킬 수 있습니다.

기회

• 암 연구 증가

Epigenetics plays a crucial role in cancer development and progression. As cancer research advances, there's a growing emphasis on understanding epigenetic modifications, such as DNA methylation and histone modifications, linked to various cancers. This drives demand for epigenetic analysis tools and technologies. For instance, companies such as Illumina and Thermo Fisher Scientific are developing advanced assays and sequencing technologies to meet the increasing need for precise epigenetic analysis in cancer research.

• Rising Personalized Medicine and Drug Development

Epigenetic profiling enables personalized medicine by tailoring treatments to an individual's unique epigenetic profile. This approach is crucial in developing targeted therapies and drug discovery, driving the adoption of epigenetic technologies by pharmaceutical and biotechnology companies. For instance, in oncology, epigenetic markers guide the creation of precise cancer treatments, improving efficacy and patient outcomes. This increasing focus on personalized therapies significantly propels the epigenetics market forward.

Restraints/Challenges

• High Cost of Research and Development

The high cost of research and development in epigenetics significantly hampers the market. Advanced technologies and methodologies require substantial investment, making it expensive for companies to conduct research and develop new products. This financial burden limits the entry of new players and restricts the pace of innovation and commercialization in the epigenetics market.

• Shortage of Skilled Professionals

The epigenetics market is constrained by a significant shortage of skilled professionals. This deficiency hampers the pace of research and development, as there are insufficient experts to advance studies and innovate in the field. The lack of adequately trained personnel limits the industry's capacity to explore and utilize the full potential of epigenetic technologies and therapies. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2023, BioLabs and Promega expanded their collaborative efforts to drive global innovation in life sciences by supporting early-stage startups. Promega GmbH, the German subsidiary of the global life sciences manufacturer, located in Walldorf, now provides advanced equipment, comprehensive services, and specialized training to BioLabs Heidelberg, enhancing their capacity to nurture emerging biotech ventures
• In November 2023, QIAGEN and Element Biosciences, Inc. entered a strategic partnership to deliver comprehensive next-generation sequencing (NGS) workflows for the innovative Element AVITI System. This collaboration aims to enhance the capabilities of NGS applications, offering robust solutions for genomics research and clinical diagnostics, thereby accelerating advancements in the field of molecular biology
• In October 2023, Zenith Epigenetics Ltd. and Cencora agreed to commercialize the ZEN-3694 program, an epigenetic therapy designed to enhance the efficacy of existing cancer treatments. This partnership seeks to leverage the synergistic potential of ZEN-3694 to improve patient outcomes by integrating it with currently marketed oncology drugs, offering a promising approach to cancer therapy
• In February 2022, Zenith Epigenetics Ltd. announced the dosing of the first patient in a clinical trial combining ZEN-3694, a BET inhibitor, with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitors, OPDIVO and YERVOY. Sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, this trial focuses on treating solid tumor cancers through innovative combination therapies
• In February 2022, Element Biosciences, Inc., the developer of a revolutionary DNA sequencing platform, partnered with Dovetail Genomics to showcase the efficacy and performance of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library preparation solutions on Element’s AVITI System. This collaboration aims to demonstrate the superior capabilities of their integrated technologies in advancing genomic research

Epigenetics Market Scope

The market is segmented on the basis of product, application, technology, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Enzymes
• Instruments and Consumables
• Kits
  • ChIP sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • Others
• Reagents

 Application

• Oncology
  • Solid Tumors
  • Liquid Tumors
• Non-Oncology
  • Inflammatory Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

 Technology

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non-coding RNA
• MicroRNA modification
• Chromatin structures

 End User

• Academic and Research Institutes
• Pharmaceutical Companies and Biotechnology Companies
• Contract Research Organizations (CROs)

Epigenetics Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, product, application, technology, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to be the fastest-growing region in the epigenetics market due to rising disposable incomes. Additionally, the increasing unmet clinical needs of patients are anticipated to further propel market growth, fostering advancements and adoption of epigenetic solutions across the region.

North America is expected to dominate the epigenetics market due to increasing research activities and innovative healthcare amenities. Continuous advancements in diagnostic processes further boost market growth in the region, positioning it as a leader in epigenetic research and applications during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Epigenetics Market Share Analysis

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 바이오테크네(미국)
• 프로메가 코퍼레이션(미국)
• GeneTex, Inc. (미국)
• 캘리포니아 태평양 바이오사이언스 주식회사(미국)
• 일루미나 주식회사(미국)
• 머크 KGaA(독일)
• QIAGEN(독일)
• F. 호프만-라 로슈 유한회사(스위스)
• 에자이 주식회사(일본)
• 노바티스 AG(스위스)
• Abcam Limited(영국)
• Diagenode sa (US)
• 액티브 모티프 주식회사(미국)
• 지모 리서치 코퍼레이션(미국)
• Thermo Fisher Scientific Inc. (미국)
• 셀센트릭(독일)
• 신닥스제약(미국)
• 뉴잉글랜드 바이오랩스(미국)
• 에피자임 주식회사(미국)
• 도메인엑스(영국)
• Agilent Technologies, Inc. (미국)
• 퍼킨엘머 주식회사(미국)
• Bio-Rad Laboratories, Inc. (미국)
• 아시스켐 주식회사 (미국)
• 엔조 라이프 사이언스(미국)
• EpiGentek Group Inc. (미국)
• BioVision Inc. (미국)

SKU-14480